Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Endocrinol Metab (Seoul). 2020 Apr 23;35(2):197-205. doi: 10.3803/EnM.2020.35.2.197. Print 2020 Jun.
The world is entering an era of disaster and chaos due to coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2. Since its first emergence in December 2019 in Wuhan, China, COVID-19 has swept through Asia and propagated throughout the world to Europe and North America. As of April 13, 1,773,084 people were infected and 111,652 people had died from COVID-19 globally, and new record levels of infection are being reported every day. Based on the data that have been amassed so far, the primary risk factors for a severe disease course or even mortality from COVID-19 are underlying diseases such as diabetes and hypertension. As the global prevalence of diabetes continues to increase, patients with endocrine diseases such as diabetes mellitus and those who are on long-term corticosteroid therapy due to adrenal insufficiency or hypopituitarism are at risk for a poor prognosis of COVID-19. As endocrinologists, we would like to briefly review the current knowledge about the relationship between COVID-19 and endocrine diseases and to discuss what we can do for the safety and health of our patients with endocrine diseases in this globally threatening situation.
由于新型冠状病毒病（COVID-19），即由严重急性呼吸系统综合征冠状病毒 2 引起的疾病，世界正进入灾难和混乱的时代。自 2019 年 12 月在中国武汉首次出现以来，COVID-19 已席卷亚洲，并传播到世界各地，包括欧洲和北美。截至 2023 年 4 月 13 日，全球已有 1773084 人感染，111652 人死于 COVID-19，每天都有新的感染记录创下新高。根据迄今为止收集的数据，COVID-19 重症甚至死亡的主要危险因素是糖尿病和高血压等基础疾病。随着全球糖尿病患病率的持续增加，糖尿病等内分泌疾病患者以及因肾上腺功能不全或垂体功能减退而长期接受皮质类固醇治疗的患者，COVID-19 的预后较差。作为内分泌学家，我们想简要回顾一下 COVID-19 与内分泌疾病之间关系的现有知识，并讨论在这种全球威胁的情况下，我们可以为患有内分泌疾病的患者的安全和健康做些什么。
